Spark licenses blindness gene therapy rights outside U.S. to Novartis
(Reuters) - Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, has licensed rights to the drug in markets outside the United States to Switzerland-based Novartis AG, it said on Wednesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Blindness | Gene Therapy | Genetics | Health | Opthalmology | Switzerland Health | USA Health